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Alfredo Juárez-Saldivar d, Olatomide A. Fadare e, Charles O. Adetunji f, Gildardo Rivera d 
a Department of Microbiology, Osun State University, Osogbo, Nigeria 
b Departamento de Microbiología e Inmunología, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Nuevo León, 66455, 
Mexico 
c Drug Research and Production Unit, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Osun State, 220005, Nigeria 
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A B S T R A C T   
Background: SARS-CoV-2 infection or COVID-19 is a major global public health issue that requires urgent 
attention in terms of drug development. Transmembrane Protease Serine 2 (TMPRSS2) is a good drug target 
against SARS-CoV-2 because of the role it plays during the viral entry into the cell. Virtual screening of phy-
tochemicals as potential inhibitors of TMPRSS2 can lead to the discovery of drug candidates for the treatment of 
COVID-19. 
Purpose: The study was designed to screen 132 phytochemicals from three medicinal plants traditionally used as 
antivirals; Zingiber officinalis Roscoe (Zingiberaceae), Artemisia annua L. (Asteraceae), and Moringa oleifera Lam. 
(Moringaceae), as potential inhibitors of TMPRSS2 for the purpose of finding therapeutic options to treat COVID- 
19. 
Methods: Homology model of TMPRSS2 was built using the ProMod3 3.1.1 program of the SWISS-MODEL. 
Binding affinities and interaction between compounds and TMPRSS2 model was examined using molecular 
docking and molecular dynamics simulation. The drug-likeness and ADMET (absorption, distribution, meta-
bolism, excretion, and toxicity) properties of potential inhibitors of TMPRSS2 were also assessed using admetSAR 
web tool. 
Results: Three compounds, namely, niazirin, quercetin, and moringyne from M. oleifera demonstrated better 
molecular interactions with binding affinities ranging from -7.1 to -8.0 kcal/mol compared to -7.0 kcal/mol 
obtained for camostat mesylate (a known TMPRSS2 inhibitor), which served as a control. All the three com-
pounds exhibited good drug-like properties by not violating the Lipinski rule of 5. Niazirin and moringyne 
possessed good ADMET properties and were stable in their interactions with the TMPRSS2 based on the mo-
lecular dynamics simulation. However, the ADMET tool predicted the potential hepatotoxic and mutagenic ef-
fects of quercetin. 
Conclusion: This study demonstrated the potentials of niazirin, quercetin, and moringyne from M. oleifera, to 
inhibit the activities of human TMPRSS2, thus probably being good candidates for further development as new 
drugs for the treatment or management of COVID-19.  
Abbreviations: ADMET, Absorption, distribution, metabolism, excretion and toxicity; BBB, Blood brain barrier; CASTp, Computed atlas of surface topography of 
proteins; COVID-19, Coronavirus Disease 2019; GMQE, Global quality estimation score; HIA, Human intestinal absorption; HOB, Human oral bioavailability; LD50, 
Lethal dose 50; QMEAN, Qualitative Model Energy Analysis; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; TMPRSS2, Transmembrane Protease 
Serine 2; RMSD, Root-mean-square deviation. 
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Introduction 
SARS-CoV-2 is an envelope and a spiked positive-stranded ribonu-
cleic acid (RNA) virus responsible for a severe acute respiratory syn-
drome (SARS) termed Coronavirus Disease 2019 (COVID-19), with some 
symptoms such as cough, sore throat, fever, pneumonia, alveolar dam-
age, and inflammatory responses in the airways ultimately leading to 
severe respiratory failure. SARS-CoV-2 possesses a 30 kb genome 
encoding non-structural proteins (viral proteases, transcription, and 
replication proteins) and structural proteins (nucleocapsid, membrane, 
envelope, and spike). The spike is a glycosylated protein that plays a 
significant role during SARS-CoV-2 infection. It recognizes and binds to 
a receptor known as angiotensin-converting enzyme 2 (ACE-2) on the 
host cell surface prior to the virus entry into host cells via receptor 
mediated endocytosis (Pandey et al. 2020). Furthermore, the successful 
internalization of SARS-CoV-2 into the human host cell is a function of 
the presence of a cellular protease Transmembrane Protease Serine 2 
(TMPRSS2), which primes the glycosylated spike protein to allow the 
virus fuse with the host membrane (Hoffmann et al. 2020). 
The critical role TMPRSS2 plays during SARS-CoV-2 infection makes 
it a good target for drug development in the treatment of COVID-19 
disease or amelioration of conditions of patients infected with the 
SARS-CoV-2 virus. Although several research efforts have been 
committed to the discovery of drugs to combat COVID-19, there has 
been no success in the development of approved antiviral drugs. The 
inhibitory activities of compounds and drugs against TMPRSS2 have 
been reported (Vivek-Ananth et al. 2020). For instance, clinically 
approved drugs such as camostat mesylate and nafamostat have been 
reported as potent inhibitors of TMPRSS2 (McKee et al. 2020). Recent in 
silico studies have identified several phytochemicals from different 
plants as potential inhibitors of TMPRSS2. Pooja et al. (2021) identified 
columbin and jatrorrhizine from Tinospora cardifolia (Willd.) Miers 
(Menispermaceae), baicalein from Scutellaria baicalensis Georgi (Lam-
iaceae), proanthocynidine A2 from Litchi chinensis Sonn. (Sapindaceae), 
and myricetin from Torreya nucifera (L.) Siebold & Zucc. (Taxaceae) as 
potential TMPRSS2 inhibitors. Furthermore, the inhibitory potentials of 
antiviral phytochemicals, including bisdemethoxycurcumin, carvacrol, 
and thymol from common Indian spices, namely Trachyspermum ammi 
(L.) Sprague (Apiaceae), Curcuma longa L. (Zingiberaceae), and Nigella 
sativa L. (Ranunculaceae) against TMPRSS2 were reported by Yadav 
et al. (2021). 
Plant-based natural products have been recognised as an excellent 
source of novel drugs. Different plant species have been converted into 
pharmacological drugs which have been applied for successful treat-
ment of several human ailments such as malaria, hypertension, and 
cancer. Small molecules derived from natural products are not only 
readily abundant, but they have also been reported to be orally active 
according to the Lipinski rule of compound druggability (Benet et al. 
2016). The plants of interest in this study include Zingiber officinalis 
Roscoe (Zingiberaceae), Artemisia annua L. (Asteraceae), and Moringa 
oleifera Lam. (Moringaceae) that have a long history of traditional uses 
as antiviral. Z. officinalis is a spice with several pharmacological prop-
erties. Chang et al. (2013) reported that fresh ginger reduced human 
respiratory syncytial virus infection by more than 70 % in human res-
piratory tract cell lines HEp-2 and 549. A study on A. annua has also 
shown that it has potential as an antiviral agent in the control of flavi-
ruses (Romero et al. 2006), human cytomegalovirus, herpes simplex 
virus, and hepatitis virus (Efferth et al. 2008). Recently, Nair et al. 
(2021) showed that A. annua extracts could inhibit SARS-CoV-2 repli-
cation in vitro. M. oleifera (also known as “drum stick or horse radish”) is 
well distributed and cultivated in Asia, Africa, Latin America, the 
Caribbean, and the Pacific Island due to its numerous nutritional and 
medicinal importance. The antiviral potentials of M. oleifera against 
herpes simplex virus, hepatitis B virus, influenza virus, Epstein–Barr 
virus, and human immunodeficiency virus have been reported (Biswas 
et al. 2020). A molecular docking study conducted by Chakotiya and 
Sharma (2020) showed that shogaol, zingerone, and zingiberene from 
Z. officinalis had higher binding affinities for TMPRSS2 compared to 
camostat mesylate, a standard TMPRSS2 inhibitor. Laksmiani et al. 
(2020) also studied the interactions between three phytochemicals from 
M. oleifera (apigenin, luteolin, and quercetin) and TMPRSS2 via molec-
ular docking. However, in this current study, molecular docking was 
performed to analyze the interactions between several phytochemicals 
from the study plants and TMPRSS2. The stability of the resulting 
protein-ligand complexes was further assessed by molecular dynamics 
simulation. 
The development of a molecule or compound into a new clinically 
acceptable drug takes an average of 12 years and cost over $1 billion 
(Mohs & Greig, 2017). However, the application of computational 
methods has shortened the period required to detect a compound that 
could be utilised as a potential clinical candidate (Lin et al. 2020). In-
teractions between several compounds and protein targets can be 
studied in silico using computer programs to select lead compounds that 
could be developed into clinical drugs. In silico screening of compounds 
does not only aid the rapid discovery of compounds with therapeutic 
values but also reduces the cost of developing new drugs. Computational 
studies also offer the opportunity of determining the ADME (Absorption, 
Distribution, Metabolism, and Excretion) and “drug-likeness” of prom-
ising natural compounds, hence, helping in ruling out compounds that 
might not be effective during the different steps of drug development 
(Lombardo et al. 2017). As researchers continue to hunt for arsenals to 
treat SARS-CoV-2 infection, the in silico evaluation of natural 
plant-derived compounds via molecular docking and molecular dy-
namics simulation can assist in the quick discovery of drugs to treat 
COVID-19. 
Therefore, in this study, compounds from three important medicinal 
plants (Z. officinalis, A. annua, and M. oleifera) were screened as potential 
inhibitors of TMPRSS2, an important protein implicated in the SARS- 
CoV-2 infection. 
Materials and methods 
Homology modelling of drug target (TMPRSS2) 
The amino acid sequence of TMPRSS2 (Uniprot accession number 
O15393) comprising 492 amino acids was retrieved from Uniprot 
database (https://www.uniprot.org/), and then used to predict the 
protein 3D structure of TMPRSS2 by homology modelling. The amino 
acid sequence of TMPRSS2 was subjected to BLAST search in the SWISS- 
MODEL (https://swissmodel.expasy.org/), an automated protein struc-
ture homology-modelling server to obtain a template protein structure. 
The BLAST search returned the crystal structure of serine protease 
hepsin in complex with inhibitor (SMTL ID 5ce1.1) as the template 
protein structure for the homology-modelling. 
The template protein structure was used to build a homology model 
of TMPRSS2 using the ProMod3 3.1.1 program of the SWISS-MODEL 
online server. The model obtained was validated using PROCHECK 
(https://servicesn.mbi.ucla.edu/PROCHECK/), ERRAT (https://service 
sn.mbi.ucla.edu/ERRAT/), and verify3D (https://servicesn.mbi.ucla. 
edu/Verify3D/). 
Identification of active sites and prediction of binding pockets in the 
TMPRSS2 model 
The computed atlas of surface topography of proteins (CASTp) server 
(http://sts.bioe.uic.edu/) was used to predict the binding pockets of the 
modelled TMPRSS2, and the distribution of actives sites residues (sub-
strate binding: Asp435, Ser460, and Gly462; catalytic: His296, Asp345, 
and Ser441) previously reported (Idris et al. 2020) in the pockets. 
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Phytochemical selection for molecular docking on TMPRSS2 protein model 
The SDF files of 2D chemical structures of the 132 phytochemicals 
were downloaded from the PubChem database (https://pubchem.ncbi. 
nlm.nih.gov/) and used for the molecular docking. Camostat mesylate, 
an approved serine inhibitor reported to have promising therapeutic 
effects against the SARS-CoV-2 virus, served as a control molecule. The 
compound list is available in Supplementary Material Tables S1-S3. 
Molecular docking of phytochemicals on TMPRSS2 protein model 
The molecular docking between phytochemicals and modelled 3D 
structure of transmembrane protease serine 2 (TMPRSS2) was per-
formed using Open babel and Autodock vina wizard on PyRx virtual 
screening tool. Compound structures (ligand) were minimized and 
converted to pdbqt format. For this analysis the receptor was treated 
rigid. The vina search space grid centre selected was X: 13.1910 Y: 
-6.0318 Z: 15.7311, and was set around reported catalytic (His296, 
Asp345, and Ser441) and substrate binding (Asp435, Ser460, and 
Gly462) residues of TMPRSS2 (Idris et al. 2020). The binding affinity 
(kcal/mol) was obtained after docking. The visualization of the inter-
action between ligands (compounds) and the TMPRSS2 protein model 
was done using BIOVIA Discovery studio visualizer 2020 and PyMOL 
software. The binding affinity obtained for the camostat mesylate, a 
known inhibitor of TMPRSS2, was set as the cut-off to select compounds 
for further analysis. 
Assessment of drug-likeness and ADMET (absorption, distribution, 
metabolism, excretion and toxicity) of phytochemicals 
The drug-likeness and ADMET properties of compounds predicted to 
be potential and potent inhibitors of TMPRSS2 were evaluated using the 
admetSAR web tool (Cheng et al. 2012). The drug-likeness was predicted 
based on the Lipinski rule of 5 (Benet et al. 2016). 
Molecular dynamics simulation 
Molecular dynamics simulation was performed using GROMACS 
version 2018.4 (Abraham et al. 2018). Ligand topologies were generated 
based on General Amber Force Field (GAFF) using 
ACPYPE-AnteChamber PYthon Parser interface (Sousa da Silva and 
Vranken, 2012), and protein topology was generated based on Amber03 
using pdb2gmx. The unit cell was defined as a dodecahedron and filled 
with TIP3P (three-site transferrable intermolecular potential) water. To 
neutralize the system, six chloride ions (Cl− ) were added. The energy 
minimization step was performed using the steepest descent minimiza-
tion with a maximum force < 10.0 kJ/mol. Then, the system was 
equilibrated in two phases. Firstly, NVT ensembled with 300 K as the 
reference temperature, and secondly, NPT ensembled with 1 bar as the 
reference pressure. Both were 100 ps long with a position restraining 
force on the heavy atoms of the protein and ligand. Once the system was 
equilibrated, a 50 ns molecular dynamic simulation was run. Analysis of 
the trajectory was composed by root-mean-square deviation (RMSD) 
calculation of the heavy atoms of the ligand and an energy decomposi-
tion analysis, which was performed using gmx-MMPBSA (Modifed Mo-
lecular Mechanics–Poisson Boltzmann Surface Area) with 100 frames 
from the last 10 ns of each molecular dynamic simulation. 
Results and discussion 
Homology modelling of TMPRSS2 and model validation 
The BLAST search of the amino acid sequence of TMPRSS2 obtained 
from the Uniprot database against the SWISS-MODEL library generated 
crystal structure of serine protease hepsin (SMTL ID 5ce1.1). The ho-
mology model for TMPRSS2 protein was then built using the crystal 
structure of serine protease hepsin as a template. The template has a 
sequence coverage of 71 % and resolution of 2.50 Å. It also shared 
sequence identity and similarity of 33.33 % and 38 %, respectively, with 
the query sequence (Table 1). Based on the report of Xiang (2006), the 
sequence similarity value obtained was suitable to generate a reliable 
model. The model obtained has a QMEAN (Qualitative Model Energy 
Analysis) value of -1.47 and global quality estimation score (GMQE) of 
0.49 based on the result from ProMod3 3.1.1 in the SWISS-MODEL 
(Table 1). For biomedical applications, protein models must be accu-
rately predicted. The QMEAN value otherwise, known as “degree of 
nativeness” indicates, how comparable the model is to the experimental 
structures. A good model is expected to have a QMEAN value close to 
zero and not less than -4.0 (Benkert et al. 2011). In the study, the 
QMEAN score (-1.47) obtained for the predicted protein model 
confirmed its good quality. The GMQE result is also reliable because the 
value (0.49) obtained falls between 0 and 1, which is the benchmark, as 
reported by Biasini et al. (2014). Based on the Ramachandran plot 
(Fig. 1), the modelled TMPRSS2 has 99.6 % of its residues in the allowed 
region, 88.6 % in the most favoured region, and 11.0 % in the additional 
allowed region. This result also supported the good quality of the protein 
model. The modelled TMPRSS2 was further validated to be of good 
quality based on the overall quality factor of 95.56 % obtained from 
ERRAT2 plot analysis (Supplementary Fig. S1). 
Identification of active sites and prediction of binding pockets on the 
TMPRSS2 model 
CASTp server predicts topographic characteristics such as cavities, 
channels, and surface pockets of proteins (Tian et al. 2018). The result of 
CASTp can reveal the position of active sites such as the binding and 
catalytic sites of proteins. It can also reveal pockets in which ligand and 
amino acid residues interaction occur. The CASTp software predicted 75 
pockets with the active site residues (His296, Asp345, Asp435, Ser460, 
and Gly462) with the exception of Ser441 distributed in 10 pockets 
(Supplementary Fig. S2). The area, volume, and residues around the 
active sites are presented in Table 2. The Asp435 residue is very 
important in the TMPRSS2 for substrate binding, recognition, and 
orientation for the catalytic process, and its presence indicates the 
trypsin-like proteolytic activity of TMPRSS2 (Vivek-Ananth et al. 2020; 
Hempel et al. 2021). Therefore, compounds that bind to the Asp435 
were taken as the potential inhibitor of TMPRSS2. The Asp435 residue 
was present in 6 pockets designated 4A, 15B, 25D, 45F, 48G, and 50H. 
Meanwhile, the catalytic residue Asp345 was present in four pockets 
(20C, 32E, 51I, and 68J), and His296 in one pocket (32E). However, the 
ligand-protein interactions were observed to occur in the TMPRSS2 
pocket designated 4A, with an area and volume size of 160.709SA and 
80.898SA, respectively (Table 2). 
Molecular docking of phytochemicals on TMPRSS2 protein model 
The result of the molecular docking of 132 phytochemicals selected 
from three medicinal plants with the TMPRSS2 protein is presented in 
Table 1 
The characteristics of template used in generating TMPRSS2 and quality 
assessment of TMPRSS2 model generated.  
Features of template used in generating TMPRSS2 model 
Template Swiss model ID 5ce1.1A 
Sequence Identity 33.33 
Resolution 2.5 Å 
Sequence similarity 0.38 
Coverage 0.71 
Template description Serine protease hepsin 
Quality assessment of the TMPRSS2 model generated 
Qualitative Model Energy Analysis (QMEAN) -1.47 
Global Quality Estimation Score (GMQE) 0.49 
RSMD 0.148 Å  
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the Supplementary Tables S1, S2, and S3.The reference compound 
camostat mesylate had a binding affinity score of -7.0 kcal/mol. Hence, 
phytochemicals with binding affinity scores of ≤ -7.0 kcal/mol were 
selected for further analysis. Twenty (20) phytochemicals had binding 
affinity scores ≤ -7.0 kcal/mol out of 132 phytochemicals with binding 
affinity scores ranging from -7.0 to -8.7 kcal/mol. The bond interaction 
between the compounds and TMPRSS2 residues are presented in 
Table 3. TMPRSS2 residues Asn398, Asp435, and Gly258 form a strong 
N− H•••O hydrogen bond type interaction with the control camostat 
mesylate. (Fig. 2a). The formation of hydrogen bond between a ligand 
and target protein is important for a molecule’s function (Wu et al. 
2012). The presence of hydrogen bonds also encourages the formation of 
stronger and robust ligand-protein complexes (Majewski et al. 2019). 
However, the numerous van der Waals, covalent, π-alkyl, and electro-
static interactions observed between study compounds and TMPRSS2 
can also help in stabilizing the ligand-protein complex. 
There was no interaction between TMPRSS2 and two compounds 
found in Z. officinalis (thujopsene and zingiberol) when the docking 
interaction output was imported into Discovery Studio for visualization. 
All the compounds with binding energy ≤ -7.0 kcal/mol except gamma- 
elemene, beta-elemene, and aromadendrene formed hydrogen bonds 
with residues on TMPRSS2 (Table 4 and Supplementary Fig. S3-S14). 
However, only five compounds, namely quercetin, glucotropaeolin, 
niazirin, and moringyne from M. oleifera, and scopolin from A. annua 
formed hydrogen bonds with the important substrate binding residue 
Asp435 (Fig. 2b – f). Our findings established that these five compounds 
could serve as potential inhibitors of TMPRSS2. Scopolin formed a weak 
carbon hydrogen (C− H•••O) bond of 3.46 Å in length (L) with the 
Asp435 residue (Fig. 2b). It also formed the same weak hydrogen bond 
interaction with residues Gly259 (L= 3.30 Å), Asp440 (L= l3.30 Å and 
3.32 Å), and Thr387 (L= 3.65 Å). It interacted with residues Asp440 (L=
2.72 Å), Gly383 (L= 1.83 Å), and Asn398 (L= 1.98 Å) with a strong 
covalent hydrogen bond (O− H•••O). Other interaction observed be-
tween scopolin and TMPRSS2 was a hydrophobic alkyl/π-alkyl bond 
involving residues Cys465 (L= 3.71 Å), Ala466 (L= 3.93 Å and 5.23 Å), 
and Cys437 (L= 3.86 Å). Scopolin (the glucoside of the coumarin sco-
poletin) has different pharmacological properties, such as antioxidant, 
antimicrobial, anticoagulant, anti-inflammatory, and anticancer prop-
erties. It has also been suggested for the treatment of osteoporosis (Park 
et al. 2020) and obesity (Park et al., 2020), that are two of the risk 
factors for SARS-CoV-2 infections. Similarly, glucotropaeolin formed a 
weak carbon-hydrogen bond with residues Asp435 (L= 3.46 Å) and 
Asp440 (L = 3.06 Å), a strong N− H•••O hydrogen bond type with 
residue Thr387 (L= 2.57 Å), and a strong O− H•••O hydrogen bond type 
with Asn398 (L= 2.43 Å), Ala386 (L= 2.48 and 2.49 Å), and Asp440 (L=
2.47 and 3.02 Å). Glucotropaeolin also formed a π-alky bond of length 
Fig. 1. Quality check on the TMPRSS2 protein model (A). The PROCHECK Ramachandran plot for the validation of the modelled TMPRSS2 protein. (B). The statistics 
from the PROCHECK Ramachandran plot. (C). The 3D structure of the modelled TMPRSS2 protein. 
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5.36 with a residue Val434 of the TMPRSS2 (Fig. 2c). Glucotropaeolin is 
a glucosinolate, which has been reported to be toxic and antinutritive 
(Al-Gendy et al. 2016). 
Quercetin formed a strong hydrogen bond (O− H•••O) with residues 
Asp435 (L= 2.46 Å), Gly385 (L= 2.37 Å), Gly383 (L= 2.21 Å), Asn398 
(L= 3.02 Å), and Asn433 (L= 2.81 Å) (Fig. 2d), while niazirin formed a 
similar bond with residues Asp435 (L= 2.78 and 3.00 Å) and Asn433 
(L= 1.82 and 1.98 Å) (Fig. 2e). A weak carbon-hydrogen (was formed 
between quercetin and Asp398 (L = 3.35 Å) and Gly259 (L= 3.44 Å) 
residues of TMPRSS2. A similar interaction was also observed between 
niazirin and the Gly259 (L= 3.29 Å) residue. Both compounds bind with 
the Ala400 residue of the TMPRSS2 through a π-alkyl bond of length 
4.70 Å and 4.80 Å for quercetin and niazirin, respectively. Moringyne 
binds to six residues of the TMPRSS2 via a strong hydrogen bond 
(O− H•••O). These residues include Asp435 (L= 2.44 Å), Asp440 (L=
3.06 Å), Gly383 (L= 2.26 Å), Asn398 (L= 2.04 and 2.52 Å), and Gly385 
(L= 2.41 Å). A weak hydrogen bond was observed between moringyne 
and two TMPRSS2 residues, including Ala434 (L= 3.48 Å) and Asp440 
(L= 3.19 Å). It also binds to the Ala 466 residue via a π-alkyl bond of 
length 4.63 Å (Fig. 2f). Moringyne is a glycoside reported to relax 
bronchioles, and hence, it is used in the treatment of asthma (Mahajan 
et al. 2009). Due to this property, it could be very useful as an adjuvant 
for the treatment of COVID-19 infections, which produce severe 
breathing difficulties. 
According to Jeffrey (1997), hydrogen bond with distances ranging 
between 2.2 – 2.5 Å is classified as strong covalent hydrogen bond, while 
moderate and weak electrostatic hydrogen bond have distances ranging 
between 2.5 – 3.2 Å and 3.2 – 4.0 Å respectively. Therefore, based on 
interaction with the binding substrate Asp435 and hydrogen bonding, 
all the biologically active constituents derived from M. oleifera (quer-
cetin, niazirin, and moringyne) could serve as potent inhibitor of 
TMPRSS2 among all the biological compounds tested. 
Assessment of drug-likeness and ADMET of phytochemicals 
According to the Lipinski rule of five, a small compound that has the 
potential to become a drug must have certain properties. The compound 
must have molecular weight less than 500, the hydrogen bond donor (H- 
Bond donor), and hydrogen bond acceptor (H-Bond acceptor) must not 
be more than 5 and 10 respectively. The calculated Log P (CLog P), 
which is the octanol–water partition coefficient logP, must not be more 
than 5 (Benet et al. 2016). All the compounds, including the control, did 
not violate any of the Lipinski rules of five (Table 5), and as such, they 
possess drug-like features. Studies on the pharmacokinetics and toxicity 
of potential drug molecules are essential. The three phytochemicals 
(niazirin, quercetin, and moringyne) exhibited the highest potential to 
inhibit TMPRSS2 based on the molecular docking result, exhibiting 
different ADMET properties (Table 6). The control compound camostat 
mesylate has good human intestinal absorption (HIA), blood brain 
barrier (BBB), and human oral bioavailability (HOB) properties. It is not 
carcinogenic, according to AMES mutagenesis prediction, and has acute 
oral toxicity of level III i.e. it has a lethal dose 50 (LD50) that is less than 
500 but greater than 5000 mg/kg (Ammar, 2017). However, camostat 
mesylate is hepatotoxic according to the admetSAR server prediction. It 
was also found in this study that quercetin and moringyne can be 
absorbed in the intestine, and none of the compounds including niazirin 
can cross the blood brain barrier. Contrarily, accumulation of quercetin 
in rat brain tissues has been reported (Ishisaka et al. 2011). The 
admetSAR program predicted the compounds as non-carcinogenic and 
not orally bioavailable. However, several approaches such as absorption 
enhancer (Aungst, 2012), chemical modification (Renukuntla et al. 
2013), and self-double-emulsifying drug delivery system (Wang et al. 
2017) methods can be used to improve the oral bioavailability of the 
compounds. According to the AMES test, quercetin was predicted as a 
mutagen with a probability of 0.9000. It has level II acute oral toxicity. 
This implies that the LD50, which is the amount of compound or drug 
required to kill 50 % of the animals on which it is being tested, is greater 
than 50 but less than 500 mg/kg (Ammar, 2017). Quercetin was also 
Table 2 
Table showing the area and volume of 10 predicted pockets containing the active 





Amino acid residues present 
Pocket 
4A 
160.709 80.898 Gly259, Ile 381, Ser382, Gly383, Gly385, 
Ala386, Thr387, Glu388, Asn398, Ala399, 
Ala400, Asn433, Val434, Asp435*, Ser436, 




37.882 10.655 Asp435*, Ser436, Cys437, Thr459, Trp461, 




29.858 4.191 Lys342, Asn343, Asn344, Asp345*, Ile346, 
Ala423, Met424, Asp458, Ser460*, Tyr474, 
Gly475, Val477, Phe480 
Pocket 
25D 
15.208 2.497 Gly428, Phe429, Gly432, Val434, Asp435*, 
Ala466, Lys467, Arg470, Pro471 
Pocket 
32E 












0.969 0.039 Ile381, Val402, Ala427, Asp435*, Tyr474 
Pocket 
51I 
0.754 0.028 Ala294, Asp345*, Asp458, Ser460* 
Pocket 
68J 
0.029 0.000 Asp345*, Asp458, Ser460*, Gly475 
Keys 
* = The active site residues. 
Table 3 
The docking scores for phytochemicals with potential capacity for inhibiting 
TMPRSS2.  





1. Zingiber officinalis 
Roscoe 
(Zingiberaceae) 
Thujopsene 442402 -8.7 
2. Zingiberol 5317270 -8.7 
3. Gamma-elemene 6432312 -8.1 
4. Beta-elemene 9859094 -8.1 
5. Aromadendrene 11095734 -8.2 
6. 
7. 






























































21. Control Camostat 
mesylate 
5284360 -7.0  
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Fig. 2. a-f. The ligand-protein interaction between TMPRSS2 and (a). Camostat mesylate (b). Scopolin (c). Glucotropaeolin (d). Quercetin (e). Niazirin (f). Mor-
ingyne. The images show the binding of the phytochemicals on the TMPRSS2 pocket (inset). 
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predicted as a hepatotoxic compound. Based on the AMES, acute oral 
toxicity, and hepatotoxicity test results of quercetin, there is a need to 
apply caution in its application as a potential TMPRSS2 inhibitor. This 
result corroborates the findings of Ammar (2017). There is a dearth of 
information about the pharmacokinetics and toxicity of moringyne, and 
further research on this compound might lead to the development of an 
excellent lead compound for the treatment of SARS-CoV-2 infection. 
Molecular dynamics simulation 
As shown in Fig. 3a, the reference compound camostat mesylate in 
complex with TMPRSS2 showed a trajectory with a clear fluctuation 
from 5 to 30 ns, but after this time, the system stabilizes around 5 Å. In 
the case of quercetin, the RMSD never reached a stable state, and at 30 
ns, the ligand moved away from the protein, therefore, causing a drastic 
reduction in the RMSD value. In contrast to niazirin and moringyne, lack 
Fig. 2. (continued). 
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of sugar moeity in the quercetin can affect its flexibility and stability 
because the sugar ring and the rotation of the glycosidic bond can 
generate several sites of interactions. The relative frequency of molec-
ular interactions in the last 10 ns of simulation from camostat mesylate, 
niazirin, and moringyne trajectories suggests that Asp440, Ser436, and 
Gly385 have significant contributions to the ligand binding because the 
three compounds bind to these residues primarily by hydrogen bonding 
(Fig. 3b). From the RMSD result, camostat mesylate is a highly flexible 
compound, therefore interacts at a low relative frequency, except for its 
hydrogen bond interaction with Asp440, Ser436, and Gly385. On the 
Fig. 2. (continued). 
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Table 4 
The bond interactions between the potential phytochemical inhibitors with binding affinities ≤ -7.0 kcal/mol and TMPRSS2.  
Compound Interaction between compounds and TMPRSS2 protein residues 
















Asp440 - - - - - 
Beta- and Gamma- 
elemene 
- - Ala400, Ile381 - - - - - - 
Aromadendrene - - Ala400, Ile381 - - - - - - 







- - - - - - 
Lumichrome Asp440, Asn398 - Ala400, Ile381 - - - - - Asn398 
Myricetin Asn433, Ile381, 
Asp440, 
Asn398, Gly259 Ala400 - - - - - - 
Quercetin Asn433, Asn398, 
Gly385, Gly383, 
Asp435 
Gly259, Asn398 Ala400 - - - - - - 
Luteolin Asp440 Asn398 Ala400, 
Ala466 
- - Ala466 Cys437 Thr387 Gly383 
Astragalin Asp440 Gly259 Val434, 
Cys465 
- - Glu388, 
Ala466, 
Gly259 
Cys437 - - 
Epicatechin Asn398, Gly385 Asn398 Ala400, 
Cys465 
- Asp440 Ala466 Cys437 Thr387 Glu389 
Apigenin Gly383, Ile381  Val434, 
Ala400 
- Asp440 - - - - 
Kaemferol Gly383 Gly259, Asn398 Ala400 - - - - - - 
Glucotropaeolin Asp440, Asn398, 
Thr387, Ala386 
Asp435, Asp440 Val434 - - - - - - 
Niazirin Asn433, Asp435 Gly259 Ala400 - - - - - - 






- - Ala466, 
Glu388 
- Thr387 Glu389 
Marumoside A Gly383, Gly385 Gly259 Ala400, 
Ile381, Val434 
- - - - - Ala386 
Moringyne Ile381, Asp440, 
Asn398, Gly385, 
Gly383, Asp435, 
Val434 Ala466 - - - - - - 
Isorhamnetin Asp440 Ile381, Gly259, 
Asn398 
Ala400 - - - - - -  
Table 5 


















Niazirin C14H17NO5 279.29 0.50 3 -0.37 -1.36 102.94 68.95 6 3 
Quercetin C15H10O7 302.24 0.00 1 1.54 -3.16 131.36 78.03 7 5 




C21H26N4O8S 494.52 0.24 10 0.24 -2.66 200.06 123.31 9 3  
Table 6 
The ADMET properties of the three phytochemicals predicted as potential inhibitors of TMPRSS2.  






















Quercetin + (0.9833) - (0.4632) - (0.5429) - (1.0000) + (0.9000) II (0.7348; 
LD50>50<500 mg/kg) 
+ (0.7500) 











- (negative); + (positive); LD50: Lethal Dose 50. 
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other hand, Ile381, Ala400, and Val434 contributed to the stability of 
niazirin by hydrophobic interactions. The most stable compound, mor-
ingyne, forms two additional hydrogen bonds with Ala386 and Asn398, 
in accordance with the docking pose. 
Conclusion 
Using computer-aided in silico analysis which include homology 
modelling, molecular docking, and molecular dynamics simulation, we 
identified three compounds from M. oleifera- niazirin, quercetin, and 
moringyne that can inhibit the activity of human TMPRSS2. The three 
compounds exhibited satisfactory ADMET properties, though the 
application of quercetin requires caution. Comparatively, the result of 
the molecular dynamics simulation suggested moringyne as the best 
phytochemical to be considered as a potential inhibitor of TMPRSS2. 
Further experimental studies on niazirin, quercetin, and moringyne are 
required to consider their application in the treatment and management 
of SARS-CoV-2 infection. 
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